Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Conditions
Hematologic Malignancies
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
O'Neal Comprehensive Cancer Center, University of Alabama, Birmingham, Alabama, United States
Contact: Study coordinator (Omer Jamy, MD)City of Hope - Phoenix, Goodyear, Arizona, United States
Contact: Study coordinator (Misam Ziwat)City of Hope National Medical Center, Duarte, California, United States
Contact: Study coordinator (Amanda Blackmon)Moffitt Cancer Center, Tampa, Florida, United States
Contact: Principal Investigator (Rory Shallis, MD)City of Hope - Atlanta, Newnan, Georgia, United States
Contact: Study coordinator (Sabarish Ayyappan)City of Hope - Chicago, Zion, Illinois, United States
Contact: Study coordinator (Neil Dunavin)Ochsner Clinic Foundation, New Orleans, Louisiana, United States
Clinical Research Alliance, Inc., Lake Success, New York, United States
New York - Presbyterian Hospital, New York, New York, United States
UNC School of Medicine, Division of Hematology, Chapel Hill, North Carolina, United States
Contact: Study coordinator (Joshua Zeidner, MD)Bon Secours St. Francis Cancer Center, Greenville, South Carolina, United States
Contact: Study coordinator (Sharif Khan, MD)Baylor Scott & White Health, Dallas, Texas, United States
Contact: Study coordinator (William Christensen, MD)MD Anderson, Houston, Texas, United States
Contact: Study coordinator (Tapan Kadia, MD)The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
Anhui Provincial Hospital, Hefei, Anhui, China
Affiliated Cancer Hospital of Chongqing University, Chongqing, Chongqing Municipality, China
Cancer prevention and treatment center of Sun Yat sen University, Guangzhou, Guangdong, China
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Affiliated Hospital of Hebei University, Baoding, Hebei, China
Henan Cancer Hospital, Zhengzhou, Henan, China
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
The First Affiliated Hospital Of Nanchang University, Nanchang, Jiangxi, China
Shengjing Hospital Affiliated to China Medical University, Shenyang, Liaoning, China
Linyi Cancer Hospital, Linyi, Shandong, China
Blood disease hospital, Chinese Academy of Medical Science, Tianjin, Tianjin Municipality, China
The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Study leads
Dragan Cicic, MD
Study Chair
SELLAS Life Sciences Group, Inc.